Please assess the completion status of the following clinical trial:

Trial Title: A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CDI is confirmed by clinical symptoms and rapid CDI test~* Subject has not been treated with medication for CDI within the last 10 days~* Subject is:~  * receiving immunosuppressive therapy (chemotherapy) or is undergoing a stem cell transplant procedure (defined as the time period from the start of conditioning prior to transplant until 6 months after infusion of stem cells) for a hematological malignancy; or~ * receiving immunosuppressive therapy (chemotherapy) for a solid tumor malignancy or following solid organ transplantation; or~ * being treated with immunosuppressive and /or anti-TNF therapy for an auto-immune disease~* Any woman of childbearing potential requires negative serum or urine pregnancy test before entry to the study~* Male and female subjects that are sexually active must agree to practice effective birth control during the study and for 30 days after the end of the study~Exclusion Criteria:~* The subject has experienced more than one previous episode of CDI within the 3 months prior to study inclusion~* Taking or requiring to be treated with prohibited medications~* Unable to take oral study medication~* Female patients that are pregnant, intend to become pregnant or are breastfeeding~* History of ulcerative colitis or Crohn's disease~* History or diagnosis of toxic megacolon or pseudomembranous colitis~* Hypersensitivity to fidaxomicin or any of its components~* Hypersensitivity to vancomycin or any of its components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fidaxomicin (Type: EXPERIMENTAL): Fidaxomicin with alternating matching placebo
- Vancomycin (Type: ACTIVE_COMPARATOR): Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).